A Cleveland hospital is kicking off a new clinical trial aimed at determining whether AI software is superior to radiologist know-how when it comes to identifying lung cancer.
Qure.ai, a multinational technology company specializing in respiratory diseases, announced its new collaboration with the University Hospitals Cleveland Medical Center on Tuesday. The healthcare complex will use Qure.ai’s qXR-LN software as a second set of eyes after radiologists examine X-ray scans. Each assessment will then be compared side-by-side.
“AI serves as an additional set of eyes for radiologists, enhancing detection by flagging lung nodules that may require further evaluation,” said Amit Gupta, an expert from the Ohio medical centre.
“The clinical trial will evaluate how many patients require follow-up CT scans, biopsies, and how many more lung cancer cases are diagnosed earlier using AI.”
Read more: Qure.ai’s qXR software helps provide Scottish woman with lung cancer diagnosis
Read more: AI capable of identifying lung cancer years before symptoms manifest
New study validates qXR efficacy
Qure.ai’s technology was recently evaluated in an investigation with over 700 participants in five countries: Indonesia, Egypt, India, Turkey and Mexico.
“CREATE [the study] achieved its primary outcome, demonstrating that qXR correctly categorizes incidental pulmonary nodules on chest X-rays as high and low-risk of malignancy compared with radiologist assessment of low-dose CT scans,” the company explained.
Additionally, using Vietnam as a model nation in this assessment, Qure.ai predicted that widespread use of its AI-powered X-ray tech in the Southeast Asian country would result in the reduction of more than 4,700 premature deaths over a five-year period.
The pharmaceutical giant AstraZeneca plc (NASDAQ: AZN) (STO: AZN) helped complete the clinical analysis. This multinational biotech company presented data from the CREATE study to the European Lung Cancer Congress on Monday.
Read more: Breath Diagnostics onboards new president and closes critical financing
Read more: Breath Diagnostics pioneers novel lung cancer breath test
Qure.ai partners with tech giant to enhance its capabilities
“Jetson” graphics processing units (GPUs) from NVIDIA Corp (NASDAQ: NVDA) (ETR: NVD) have proven to be a valuable component in Qure.ai’s machine learning-augmented respiratory diagnostics system.
“Jetson GPUs process scans instantly on-site, cutting down delays and ensuring faster clinical decisions,” Qure.ai said in a social media post. “What once took 14 days now happens in hours.”
Qure.ai also uses NVIDIA’s H100 and A100 GPUs to train its algorithms at one of the company’s corporate offices in Bangalore, India.
“AI is going to revolutionize the entire healthcare industry,” said Sagar Sen — VP Operations, Head of Program Management at Qure.ai.
In July last year, the medical tech developer obtained a Class III medical device licence from Health Canada, enabling Qure.ai to distribute its technology throughout the Canadian healthcare market.
rowan@mugglehead.com
